s well as malaria, they are also evaluating Artemisone for the treatment of human cytomegalovirus (CMV) infections, including stem cell transplant CMV and congenital CMV.
Results from a Phase 1 trial published in Nature Medicine show that an investigational malaria vaccine demonstrated durable protection in healthy, malaria-naive adults in the U.S. from infection for >1 year post-immunization.
A combination drug therapy widely used to treat malaria in adults - dihydroartemisinin-piperaquine (DP) - also protects pregnant women and their fetuses from the disease.
Imprimis Pharmaceuticals announced that it has made available a compounded formulation of pyrimethamine and leucovorin as a lower-cost alternative to Daraprim (pyrimethamine; Turing Pharmaceuticals).
The Nobel Assembly at Karolinska Institutet has awarded the 2015 Nobel Prize in Physiology or Medicine to researchers for their discoveries concerning novel therapies against infections caused by roundworm parasites and malaria.
Turing Pharmaceuticals has agreed to reduce the cost of its drug Daraprim (pyrimethamine) after receiving significant criticism due to a sudden increase in the price of the medication.
An investigational enzyme inhibitor may be able to cure malaria in a single dose when used in conjunction with another drug, and also be utilized as a preventative treatment.
Anti-malarial drugs may be a potential treatment option for Parkinson's disease, according to researchers from Nanyang Technological University, McLean Hospital, and Harvard Medical School.
A pathogen can develop resistance faster in a "pocket" of the body where only one drug is present compared to where no pockets exist, a new study published in the Proceedings of the National Academy of Sciences has shown.
Many patients prescribed hydroxychloroquine exceed the safety guidelines for daily dosing, according to a study presented at the annual meeting of the Association for Research in Vision and Ophthalmology.
New policy guidelines issued by the White House Office of Science and Technology Policy are calling for U.S. universities to carefully monitor their life sciences research on dangerous pathogens and toxins for both benefits and risks.
The parasite that causes malaria is growing increasingly resistant to the drugs commonly used to fight it, according to new surveillance reports.
Mylan announced it has received final approval for its Abbreviated New Drug Application (ANDA) for Atovaquone and Proguanil HCl Tablets, the generic version of GlaxoSmithKline's Malarone.
Scientists have identified an antigen, PfSEA-1, that generates antibodies hindering the ability of malaria parasites to multiply. Results of this research are published in the journal Science.
According to data published in a supplement of the CDC's Morbidity and Mortality Weekly Report (MMWR), there were 1,925 malaria reported in the U.S. in 2011, a 14% increase since 2010.
U.S. researchers announced promising results from a Phase 1 clinical trial of Sanaria's PfSPZ Vaccine to combat malaria.
The FDA has approved label changes for mefloquine HCl, including a boxed warning regarding serious neurologic and psychiatric side effects.
This patient information fact sheet provides information on the definition, causes, symptoms, treatments, and preventative measures for malaria.
A pediatric malaria vaccine is effective in reducing episodes of clinical malaria, but its efficacy declines precipitously within four years.
Artesunate, a drug used in the treatment of severe malaria, may or may not be associated with hemolytic anemia, so the U.S. Centers for Disease Control and Prevention recommends close monitoring of patients treated with the drug for four weeks after administration of the agent.
Mylan announced that the FDA has approved its Abbreviated New Drug Application (ANDA) for Quinine Sulfate Capsules, the generic version of Mutual Pharmaceutical's Qualaquin.
For infants, vaccination with the RTS,S/AS01 vaccine, coadministered with Expanded Program on Immunization (EPI) vaccines, is associated with modest protection against clinical and severe malaria.
Implementation of a series of national-scale pilot programs designed to increase the access and use of quality-assured artemisinin-based combination therapies (QAACTs) for malaria by the Affordable Medicines Facility-malaria (AMFm) has improved the availability, price, and market share of QAACTs.
From 2001-2010, an increase was seen in artemisinin resistance in Plasmodium falciparum (P. falciparum) on the Thailand-Myanmar border, which was largely attributable to parasite genetics.
Fixed-dose, combination pyronaridine-artesunate treatment is as effective as mefloquine plus artesunate in treating malaria infection.
Malaria kills more people each year than previously recognized -- nearly 1.2 million people worldwide -- with more than 40% of deaths occurring in older children and adults.